Beta Bionics, Inc. (NASDAQ:BBNX) CFO Sells $26,781.33 in Stock

Beta Bionics, Inc. (NASDAQ:BBNX) CFO Stephen Feider sold 1,497 shares of the stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $17.89, for a total value of $26,781.33. Following the sale, the chief financial officer now owns 45,503 shares in the company, valued at approximately $814,048.67. This trade represents a 3.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Beta Bionics Trading Up 0.5%

BBNX stock opened at $19.55 on Friday. Beta Bionics, Inc. has a 12-month low of $8.89 and a 12-month high of $24.50. The firm has a fifty day moving average price of $12.90.

Beta Bionics (NASDAQ:BBNX) last posted its earnings results on Tuesday, May 6th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.01).

Analyst Ratings Changes

A number of research firms have commented on BBNX. Stifel Nicolaus began coverage on shares of Beta Bionics in a report on Monday, February 24th. They set a “buy” rating and a $25.00 target price for the company. Wolfe Research initiated coverage on shares of Beta Bionics in a report on Friday, May 30th. They set an “outperform” rating and a $20.00 price objective for the company. Leerink Partnrs upgraded shares of Beta Bionics to a “strong-buy” rating in a report on Monday, February 24th. Piper Sandler started coverage on shares of Beta Bionics in a research report on Monday, February 24th. They set an “overweight” rating and a $26.00 price target on the stock. Finally, Robert W. Baird started coverage on shares of Beta Bionics in a report on Thursday, February 20th. They issued a “neutral” rating and a $20.00 price target for the company. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.13.

Institutional Trading of Beta Bionics

Hedge funds and other institutional investors have recently modified their holdings of the business. Strs Ohio bought a new stake in shares of Beta Bionics during the first quarter valued at about $29,000. Corebridge Financial Inc. bought a new stake in Beta Bionics during the 1st quarter worth approximately $79,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Beta Bionics during the 1st quarter worth approximately $95,000. MetLife Investment Management LLC bought a new stake in Beta Bionics during the 1st quarter worth approximately $102,000. Finally, Deutsche Bank AG bought a new stake in Beta Bionics during the 1st quarter worth approximately $148,000.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.